A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
Farsad Eskandary(Medical University of Vienna), Georg A. Böhmig(Medical University of Vienna), Lukas Baumann(Statistics Austria), Ammon Handisurya(Medical University of Vienna), Anton Staudenherz, Marie‐Bernadette Aretin(Vienna General Hospital), J. Reeve(University of Alberta), Christopher C. Kaltenecker(Medical University of Vienna), Rainer Oberbauer(Medical University of Vienna), Heinz Regele(University of Vienna), Gregor Bond, Philip F. Halloran(University of Alberta), Helmuth Haslacher(Medical University of Vienna), Luis Hidalgo(University of Wisconsin–Madison), Nicolas Kozakowski(Medical University of Vienna), Markus Wahrmann(Medical University of Vienna), Martin Posch(Medical University of Vienna)
Cited by 302
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence
|American Journal of Transplantation|2011|1.6k
International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
|Kidney International|1993|1.5k
Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft Rejection
|American Journal of Transplantation|2003|1.1k